Quantitative CT Perfusion and Radiomics Reveal Complementary Markers of Treatment Response in HCC Patients Undergoing TACE.

ABSTRACT: Background: Hepatocellular carcinoma (HCC), the most prevalent primary malignancy of the liver, is commonly treated with transarterial chemoembolization (TACE), a locoregional therapy that combines targeted intra-arterial chemotherapy with selective embolization to induce tumor ischemia and necrosis. However, current methods for monitoring the treatment response-such as the RECIST and mRECIST-often fail to detect early or subtle biological changes, such as tumor necrosis or microstructural remodeling, and therefore may underestimate the therapeutic effects, especially in cases with minimal or delayed tumor shrinkage. Thus, there is a critical need for quantitative imaging strategies that can improve early response assessment and guide more personalized treatment decision-making. The

SUBMITTER: Fezoulidis N 

PROVIDER: S-EPMC12691162 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature